Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dirk Deleu, Beatriz Garcia Canibano, Osama Elalamy, Mohamed Sayed Abdelmoneim & Amir Boshra. (2023) Practical Guidance on the Use of Cladribine Tablets in the Management or Relapsing Multiple Sclerosis: Expert Opinion from Qatar. Degenerative Neurological and Neuromuscular Disease 13, pages 81-88.
Read now
Read now
Raed Alroughani, Jihad Inshasi, Abdullah Al-Asmi, Abdulradha Alqallaf, Abdulla Al Salti, Ahmed Shatila, Amir Boshra, Beatriz Canibano, Dirk Deleu, Isa Al Sharoqi & Jaber Al Khabouri. (2020) Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Postgraduate Medicine 132:4, pages 368-376.
Read now
Read now
Articles from other publishers (16)
Georgios Gakis, Ioannis Angelopoulos, Ioannis Panagoulias & Athanasia Mouzaki. (2024) Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation. Autoimmunity Reviews 23:2, pages 103480.
Crossref
Crossref
Daniela Rau, Sara Eichau, Giovanna Borriello, João Cerqueira & Carola Wagner. (2023) Assessment of the treating physicians’ first-hand experience with handling and satisfaction of ofatumumab therapy: findings from the PERITIA survey conducted in Europe. BMC Neurology 23:1.
Crossref
Crossref
Vasileios-Periklis Stamatellos & Georgios Papazisis. (2023) Safety and Monitoring of the Treatment with Disease-Modifying Therapies
(DMTs) for Multiple Sclerosis (MS). Current Reviews in Clinical and Experimental Pharmacology 18:1, pages 39-50.
Crossref
Crossref
Elyse Swallow, Timothy Pham, Oscar Patterson-Lomba, Lei Yin, Andres Gomez-Lievano, Jingyi Liu, Tom Tencer & Komal Gupte-Singh. (2023) Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison. Multiple Sclerosis and Related Disorders 71, pages 104551.
Crossref
Crossref
Mirna Matni, Bassem Yamout, Salam Koussa, Chaker Khamis, Lora Fleifel, Shahdak Sharifi & Omneya Mohamed. (2022) Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon. Multiple Sclerosis and Related Disorders 67, pages 104169.
Crossref
Crossref
Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Serkan Ozakbas,Olga Skibina, Jens Kuhle, Suzanne Hodgkinson, Cavit Boz, Raed Alroughani, Jeannette Lechner-Scott, Michael Barnett, Guillermo Izquierdo, Alexandre Prat, Dana Horakova, Eva Kubala Havrdova, Richard Macdonell, Francesco Patti, Samia Joseph Khoury, Mark Slee, Rana Karabudak, Marco Onofrj, Vincent Van Pesch, Julie Prevost, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt & Helmut Butzkueven. (2022) Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, pages jnnp-2022-330104.
Crossref
Crossref
Stella A Glasmacher, Patrick KA Kearns, Zackary Hassan, Peter Connick, Simone Tauber, Kathrin Reetz, Peter Foley & Siddharthan Chandran. (2022) The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 63, pages 103837.
Crossref
Crossref
Veronica Tsin Fong Voo, Helmut Butzkueven, Jim Stankovich, Terence O'Brien & Mastura Monif. (2021) The development and impact of cladribine on lymphoid and myeloid cells in multiple sclerosis. Multiple Sclerosis and Related Disorders 52, pages 102962.
Crossref
Crossref
Stanley Cohan, Jinender Kumar, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic & Tom Tencer. (2021) Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison. CNS Drugs 35:7, pages 795-804.
Crossref
Crossref
Alexandra Simpson, Ellen M. Mowry & Scott D. Newsome. (2021) Early Aggressive Treatment Approaches for Multiple Sclerosis. Current Treatment Options in Neurology 23:7.
Crossref
Crossref
Aurora Zanghì, Antonio Gallo, Carlo Avolio, Rocco Capuano, Matteo Lucchini, Maria Petracca, Simona Bonavita, Roberta Lanzillo, Diana Ferraro, Erica Curti, Maria Buccafusca, Graziella Callari, Stefania Barone, Giuseppe Pontillo, Gianmarco Abbadessa, Valeria Di Francescantonio, Elisabetta Signoriello, Giacomo Lus, Patrizia Sola, Franco Granella, Paola Valentino, Massimiliano Mirabella, Francesco Patti & Emanuele D'Amico. (2021) Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics 18:2, pages 1166-1174.
Crossref
Crossref
N.A. Avxentyev, M.V. Davydovskaya, Y.V. Makarova, M.Yu. Frolov & D.L. Klabukova. (2021) Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:8, pages 30.
Crossref
Crossref
Ali Tafazzoli, Ameya Chavan, Gerard Harty, Jorgen Moller & Schiffon L. Wong. (2020) Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis. Advances in Therapy 37:9, pages 3791-3806.
Crossref
Crossref
Elyse Swallow, Oscar Patterson-Lomba, Lei Yin, Rina Mehta, Corey Pelletier, David Kao, James K Sheffield, Tim Stonehouse & James Signorovitch. (2020) Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. Journal of Comparative Effectiveness Research 9:4, pages 275-285.
Crossref
Crossref
Petri Mankinen, Tuomas Lundström, Erkki Soini, Marja-Liisa Sumelahti, Juhani Ruutiainen, Ulla Niskala & Elina Järvinen. (2019) Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis. Advances in Therapy 37:2, pages 800-818.
Crossref
Crossref
Renée Else Michels, Maria de Fransesco, Koshu Mahajan, Gerald J. D. Hengstman, Krijn M. H. Schiffers, Sangeeta Budhia, Gerard Harty & Marieke Krol. (2019) Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Applied Health Economics and Health Policy 17:6, pages 857-873.
Crossref
Crossref